Abstract
The aim of this study is to evaluate the short-term effects of a single intravitreal injection of 1.25 mg Bevacizumab combined with 300 lg/0.1 mL Diclofenac (IVB/D) versus 1.25 mg intravitreal Bevacizumab (IVB) alone in the treatment of naive diabetic macular edema (DME). In this prospective, randomized clinical trial, 80 eyes were included in the final analysis; 42 and 38 of which in the IVB and IVB/D groups, respectively. The primary outcome measure was a change in best-corrected visual acuity (BCVA) in logMAR at week 4. The secondary outcomes included changes in central macular thickness (CMT), macular volume, and potential injection-related complications. Significant improvement of BCVA was demonstrated in both study arms (mean reductions in LogMAR: −0.088 ± 0.278, −0.228 ± 0.330 for IVB and IVB/D, respectively). The difference in BCVA changes was in favor of IVB/D; however, not to a statistically significant level (P = 0.160). Significant reduction of CMT was documented in both study arms (mean reductions: 82.43 ± 160.09 and 153.26 ± 163.85 for IVB and IVB + IVD, respectively). Comparison of CMT changes between groups showed that IVB/D reduced CMT more than that of IVB (P = 0.04). Effects on macular volume corresponded to those of CMT. No injection-related complications or significant alterations in intraocular pressure were observed in any of the study arms. In treatment-naive DME, superiority of IVB/D combination therapy over IVB monotherapy may exist; especially as regards anatomical features. In our therapeutic arsenal for DME, IVD can be added as an adjunct to Bevacizumab.
Similar content being viewed by others
References
Ehrlich R, Harris A, Ciulla TA, Kheradiya N, Winston DM, Wirostko B (2010) Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmol 88(3):279–291
Bandello F, Casalino G, Loewenstein A, Goldstein M, Pelayes D, Battaglia Parodi M (2014) Pharmacological approach to diabetic macular edema. Ophthalmic Res 51(2):88–95
Arevalo JF (2013) Diabetic macular edema: current management 2013. J Diab 4(6):231–233
[EDTRS] Early Treatment Diabetic Retinopathy Study research group (1985) Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103:1796–1806
Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M (2006) Intravitreal triamcinolone for refractory diabetic macular edema: 2-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113(9):1533–1538
Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A (2006) Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26(9):999–1005
Scholl S, Kirchhof J, Augustin AJ (2010) Pathophysiology of macular edema. Ophthalmologica 224(Suppl 1):8–15
Soheilian M, Karimi S, Ramezani A, Montahai T, Yaseri M, Soheilian R, Peyman GA (2015) Intravitreal Diclofenac versus intravitreal Bevacizumab in naive diabetic macular edema: a randomized double-masked clinical trial. Int Ophthalmol 35(3):421–428
Saghaei M (2004) Random allocation software for parallel group randomized trials. BMC Med Res Methodol 4:26
Chylack LT Jr, Leske MC, McCarthy D, Khu P, Kashiwagi T, Sperduto R (1989) Lens opacities classification system II (LOCS II). Arch Ophthalmol 107(7):991–997
Maldonado RM, Vianna RN, Cardoso GP, de Magalhães AV, Burnier MN Jr (2011) Intravitreal injection of commercially available ketorolac tromethamine in eyes with diabetic macular edema refractory to laser photocoagulation. Curr Eye Res 36(8):768–773
Faghihi H, Roohipoor R, Mohammadi SF, Hojat-Jalali K, Mirshahi A, Lashay A, Piri N, Faghihi SH (2008) Intravitreal Bevacizumab versus combined Bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol 18(6):941–948
Schmid KE, Neumaier-Ammerer B, Stolba U, Binder S (2006) Effect of grid laser photocoagulation in diffuse diabetic macular edema in correlation to glycosylated haemoglobin (HbA1c). Graefes Arch Clin Exp Ophthalmol 244:1446–1452
Wilkinson-Berka JL (2004) Vasoactive factors and diabetic retinopathy. vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr Pharm Des 10:3331–3347
Elbendary AM, Shahin MM (2011) Intravitreal Diclofenac versus intravitreal triamcinolone acetonide in the treatment of diabetic macular edema. Retina 31(10):2058–2064
Preud’homme Y, Demolle D, Boeynaems JM (1985) Metabolism of arachidonic acid in rabbit iris and retina. Invest Ophthalmol Vis Sci 26(10):1336–1342
Cheng T, Cao W, Wen R, Steinberg RH, LaVail MM (1998) Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Müller cells. Invest Ophthalmol Vis Sci 39(3):581–591
Nauck M, Roth M, Tamm M, Eickelberg O, Wieland H, Stulz P, Perruchoud AP (1997) Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am J Respir Cell Mol Biol 16(4):398–406
Kothari HV, Lee WH, Ku EC (1987) An alternate mechanism for regulation of leukotriene production in leukocytes: studies with an anti-inflammatory drug, sodium Diclofenac. Biochem Biophys Acta 921:502–511
Hariprasad SM, Callanan D, Gainey S, He YG, Warren K (2007) Cystoid and diabetic macular edema treated with nepafenac 0.1 %. J Ocul Pharmacol Ther 23(6):585–590
Shimura M, Nakazawa T, Yasuda K, Nishida K (2007) Diclofenac prevents an early event of macular thickening after cataract surgery in patients with diabetes. J Ocul Pharmacol Ther 23(3):284–291
Callanan D, Williams P (2008) Topical nepafenac in the treatment of diabetic macular edema. Clin Ophthalmol 2(4):689–692
Endo N, Kato S, Haruyama K, Shoji M, Kitano S (2010) Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmol 88(8):896–900
Warren KA, Bahrani H, Fox JE (2010) NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. Retina 30(2):260–266
Reis AC, Vianna RN, Reis RS, Cardoso GP (2010) Intravitreal injection of ketorolac tromethamine in patients with diabetic macular edema refractory to retinal photocoagulation. Arq Bras Oftalmol 73(4):338–342
Soheilian M, Karimi S, Ramezani A, Peyman GA (2010) Pilot study of intravitreal injection of Diclofenac for treatment of macular edema of various etiologies. Retina 30(3):509–515
Durairaj C, Shah JC, Senapati S, Kompella UB (2009) Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR). Pharm Res 26(5):1236–1260
Acknowledgments
The authors are very grateful to the patients and their relatives for their collaboration with this research. This survey was conducted with the cooperation of Isfahan University of Medical Sciences (IUMS) and Isfahan Eye Research Center (IERC). This work was supported by Isfahan University of Medical Sciences (Grant Number 391041).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no proprietary interest in the materials presented herein.
Rights and permissions
About this article
Cite this article
Ghanbari, H., Kianersi, F., Sonbolestan, S.A. et al. Intravitreal Diclofenac plus Bevacizumab versus Bevacizumab alone in treatment-naive diabetic macular edema: a randomized double-blind clinical trial. Int Ophthalmol 37, 867–874 (2017). https://doi.org/10.1007/s10792-016-0335-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10792-016-0335-z